With the licensing agreement between Treeway and Ferrer in place, FNP122 (formerly TW001) has now entered clinical stage phase III with the initiation of the ADORE study (ALS Deceleration study with Oral Edaravone). In a large-scale double-blind placebo-controlled...
Barcelona and Tilburg, 20 October 2021 – Today, Ferrer, an international pharmaceutical company focused on pulmonary vascular and interstitial lung diseases and neurological disorders, and Treeway, a clinical-stage biotechnology company, announced they have entered...
On Thursday April 18, Treeway’s CEO Inez de Greef is a speaker at the Rare Diseases Symposium. The second edition of the Rare Disease Symposium, organized by HollandBIO, is about challenging the status quo and the development of orphan drugs. Inez will talk about...
This week, the Australian Motor Neurone Disease Symposium takes place in Melbourne, Australia. Our CEO, Inez de Greef-van der Sandt, will present the clinical development of TW001 by Treeway...
Op maandag 9 april wordt in samenwerking met het Jeroen Bosch Ziekenhuis een maatschappelijk symposium georganiseerd rondom het thema ALS. Vanuit drie invalshoeken zal het thema worden geduid. Inez de Greef, CEO van Treeway, zal spreken over de zoektocht naar een...
We are extremely proud on winning The Shay Rishoni Patient Impact Award. This award recognizes and rewards ALS/MND patients whose activities have made significant and outstanding contributions to ALS/MND research and drug discovery efforts. The award aims to...
